ADC Therapeutics SA (ADCT)
NYSE: ADCT
· Real-Time Price · USD
3.40
0.02 (0.59%)
At close: Jun 17, 2025, 10:53 AM
0.59% (1D)
| Bid | 3.39 |
| Market Cap | 336.71M |
| Revenue (ttm) | 70.19M |
| Net Income (ttm) | -149.84M |
| EPS (ttm) | -1.42 |
| PE Ratio (ttm) | -2.39 |
| Forward PE | -2.61 |
| Analyst | Buy |
| Ask | 3.4 |
| Volume | 196,432 |
| Avg. Volume (20D) | 553,484 |
| Open | 3.35 |
| Previous Close | 3.38 |
| Day's Range | 3.26 - 3.42 |
| 52-Week Range | 1.05 - 4.13 |
| Beta | 1.96 |
About ADCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ADCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ADCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+37.12%
ADC Therapeutics shares are trading higher after t...
Unlock content with
Pro Subscription
1 month ago
+9.77%
ADC Therapeutics shares are trading higher after the company announced data from preclinical studies of three exatecan-based antibody drug conjugates targeting Claudin-6, prostate-specific membrane antigen and Alanine, Serine, Cysteine Transporter 2
2 months ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...
